Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-0502 vs Fulvestrant in ER+/HER2- Advanced Breast Cancer
NCT06954961Phase 3Recruiting
- Sponsor
- InventisBio
- Start
- Sep 2022
- Primary completion
- Nov 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 3 trial of taragarestrant in breast cancer, sponsored by InventisBio. Started Sep 2022; status: recruiting.
02
Drugs
taragarestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06954961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954961.